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Abstract
Background: Bacteria can adhere to the surface of indwelling urinary devices and 
forming a biofilm lead to complete blocking to the lumen of the urinary catheter 
and represent a site of spreading infections.
Methods: This study aimed to evaluate the effect of ciprofloxacin (CIP), N-ace-
tylcysteine (NAC) and salicylate (SAL) alone and in combinations on both biofilm 
production and pre-formed mature biofilms on microtiter plates and urinary tract 
catheter segments. 
Results: Ciprofloxacin at MIC, 1/2MIC, 1/4MIC and 1/8MIC inhibited biofilm pro-
duction on microtiter plates by 74.36%, 69.55%, 52.41% and 42.37%, respectively 
and disrupted the pre-formed biofilms by 53.77%, 47.72%, 42.13% and 34.78%, 
respectively. Ciprofloxacin also inhibited the biofilm production on catheter seg-
ments by 67.35% and 55.22% in presence of MIC and 1/4MIC, respectively and 
disrupted the pre-formed biofilms by 65.83% in presence of MIC and 51.55% in 
presence of 1/4MIC. NAC and SAL each alone inhibited biofilm production by up 
to 71% and 68% on microtiter plates and by up to 62% and 68% on catheter 
segments, respectively and disrupted pre-formed biofilms by up to 67% and 62% 
from microtiter plates and by up to 61% and 62% from catheter segments, respec-
tively. Ciprofloxacin / N-acetylcysteine showed higher inhibitory effect on biofilm 
production and higher disruptive effect on the pre-formed biofilms than ciprofloxa-
cin / Salicylate. When salicylate was added to the ciprofloxacin / N-acetylcysteine 
combination it enhanced the biofilm inhibition to become up to 99% and the 
disruptive effect became up to 98%. 
Conclusion: our results revealed the great effect of the tested combinations on 
inhibition of bacterial adherence and in removal of pre-formed biofilms.
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Introduction 
Urinary catheters are commonly used in urologic practice (1). 
Although urinary catheterization is valuable, it may lead to 
catheter obstruction, encrustation, stone formation and bio-
film formation (2, 3). Biofilm is a population of cells growing 
on a surface and enclosed in an exopolysaccharide matrix 
which may lead to complete blocking to the lumen of the 
catheter (4). Because of their resistance to antibiotics, biofilm 
bacteria are a major concern to clinical microbiologists and 
clinicians engaged in the treatment of infectious diseases. 
Eradication of biofilm bacteria is often found to be difficult 
(5, 6). For this reason, biofilm infections are persistent, and 
individuals often show recurring symptoms following antibi-
otic therapy.
Many compounds have therefore been investigated in vitro 
for their potential to reduce biofilm formation. The inhibitory 
effects on biofilm production of non-antibiotic compounds 
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such as nonsteroidal anti-inflammatory drugs and mucolytics 
have been reported. NAC is a non antibiotic drug that has an-
tibacterial properties. It is a mucolytic agent and a well estab-
lished antioxidant (7) that disrupts disulphide bonds in mu-
cus and reduces the viscosity of secretions. N-acetylcysteine 
(NAC) decreases biofilm formation by a variety of bacteria (8, 
9) and reduces the production of extracellular polysaccharide 
matrix (10) while promoting the disruption of mature biofilm 
(8, 9). NAC is widely used in medical practice via inhalation, 
oral and intravenous routes (11, 12), and it has an excellent 
safety profile (13). Aspirin (acetylsalicylic acid), a commonly 
used NSAID, is broken down by the body into salicylic acid 
(14) to inhibit production of cyclo-oxygenase (COX), which 
is the key to the body’s inflammatory response. Salicylates 
have also been shown to decrease biofilm formation by a va-
riety of bacteria (15-18). Since the antimicrobial susceptibility 
of biofilm-associated bacteria is enhanced in disrupted bio-
films (19), it is conceivable that an antibiofilm/ antimicrobial 
agent combination would be synergistic (10). In this work, 
we study the effect of ciprofloxacin, N-acetylcysteine and 
salicylate each alone and in combinations on biofilm forma-
tion on urinary catheter surface to select a suitable treatment 
for biofilm-associated infections to decrease hospitalization 
time and cost.
Material and methods
Bacterial strains and compounds
One tested strain of Pseudomonas aeruginosa (Ps22) recov-
ered from urine samples identified according to Koneman et 
al. (20). It showed to be capable of high biofilm production 
according to Christensen et al. (21), were used in this study. 
The strain were kept as stock culture frozen at - 20oC. Prior 
to use in experiments, it was subcultured on to nutrient agar 
plates.
Drugs
Preparation of stock solution of ciprofloxacin Cip (Rambxy, 
England), was performed in accordance with the manufac-
turer’s instructions. Sodium salicylate was purchased from 
BDH, England, N-acetylcysteine from Sigma, USA.
Determination of MIC and MBC of the drugs 
against planktonic isolates
MIC and MBC were determined by broth microdilution meth-
od, according to CLSI (22). Briefly, microtiter plates each of 
which containing 50 µl of twice the final concentration of 
serially diluted agents (from 2048µg/ml to 0.125µg/ml for 
ciptrofloxacin, from 25µg/ml to 2000µg/ml for sodium sa-
licylate and from 0.06, 0.12, 0.25, 0.5, 1, 2, 4, 8 mg/ml for 
NAC) in Muller Hinton Broth (MHB) was inoculated by adding 
stationary-phase culture (50 µl; 106 CFU/ml) filling the wells in 
the rows numbered from 1 to 8. The columns 11 and 12 were 
reserved as controls. Plates were sealed and incubated with-
out shaking at 37°C. MICs were determined as the minimum 
antibiotic concentrations that prevented detectable growth 
within the wells after 24 h. Endpoints were determined spec-
trometrically at 600 nm using an Anthos ht III microtiter plate 
reader (Anthos Labtec Instruments, Salzburg, Austria). The 
minimum bactericidal concentration (MBC) was determined 
by the absence of growth or less than five colonies when 10µl 
of MIC and above concentrations was transferred from the 
wells that neutralized with 2.5 µl of universal neutralizer (1.0 
g/l L-histidine, 1.0 g/l L-cysteine, 2.0 g/l reduced glutathione) 
reported by Harrison et al. (23) to Mueller Hinton agar plates 
after. Plates incubated for 24h at 37oC. Tolerance for cipro-
floxacin is defined as an MBC/MIC ratio of ≥ 32. The drug is 
considered bactericidal if MBC/MIC≤ 4.
Effect of ciprofloxacin, N-acetylcysteine and 
salicylate each alone and in combination on the 
bacterial adherence to microtiter plates
The effect of 8MIC, 4MIC, 2MIC, MIC, 1/2MIC, 1/4MIC, 
1/8MIC of ciprofloxacin on the biofilm formation and on the 
pre-formed biofilm of the Ps22 isolate was tested on the 
microtiter plates. Also different concentrations (5, 10, 25, 50, 
75, 100 and 150 µg/ml) of the sodium salicylate and differ-
ent concentrations (0.06, 0.12, 0.25, 0.5, 1, 2, 4 and 8 mg/
ml) of N-acetylcysteine were used for this study. Culture of 
the tested isolate was diluted, standardized and distributed in 
microtiter plates as following; enough isolated colonies from 
an 18- to 24-hrs TSA culture were picked up and inoculated in 
5 ml of Mueller Hinton Broth at 1 x 108 CFU/ml (OD of 0.1 at 
660 nm). The standardized inoculum diluted 1:50 in Mueller 
Hinton Broth (0.2 ml to a 10 ml tube of broth). 
To determine the effect on the biofilm formation 50μl of this 
adjusted inoculum was added to each well containing 50μl 
of four fold the final concentration of the drug. 100µl of the 
free medium were placed into each row of a 96-well flat-
bottom microtiter plate (Nuclon Delta, Nunc, Denmark), so 
each wells contained a final volume of 200 µl. The columns 
11 and 12 were reserved as controls. The positive control 
was composed of 150μl of the media and 50μl of inoculum 
solution. The negative control was composed of 200μl of the 
same culture medium. The plates were statically incubated for 
24 h at 37oC to allow for biofilm formation. After incuba-
tion, the contents of the plates were gently aspirated with a 
Pasteur pipette. The plates were then washed four times with 
sterile phosphate buffered saline (pH 7.2) and fixed overnight 
with Bouin’s fixative reagent. The fixative reagent was then 
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removed by washing the wells several times with 50% etha-
nol and wells were stained by crystal violet solution. Excess 
stain was washed with running distilled water. Plates were 
air-dried before reading optical densities (OD) at 490 nm as 
described by Christensen et al. (21). To evaluate the possible 
effect of the drug on growth and cell density which influence 
slime formation, the OD of the broth culture in the wells of 
each microtiter plate were measured at 490 nm before as-
piration and staining of the plates and the slime index were 
determined according to Perez- Giraldo et al. (24). Mean of 
three trials was calculated.
The slime index (SI) = 100 x (mean density of biofilm with 
tested agent /mean growth with tested agent) / (mean den-
sity of biofilm without tested agent /mean growth without 
tested agent).
To determine the effect on the pre-formed biofilm, the bio-
films were allowed to form for 24 h then the media were 
aspirated, rinsed with PBS and 200μl of the media contain-
ing different concentrations of the antimicrobials were added 
and incubated for additional 24 h. The columns 11 and 12 
were reserved as controls. OD of biofilm determined spectro-
photometrically by reading optical densities (OD) at 490 nm 
as described above.
Minimum biofilm inhibitory concentration (MBIC) and mini-
mum biofilm eradicating concentration (MBEC) of each an-
timicrobial were calculated on established biofilm. Minimum 
biofilm inhibitory concentration (MBIC) was defined as no 
visible growth after incubation for 24hr in the presence of a 
preformed biofilm and the antibiotic compared with an un-
treated control and it was calculated before aspiration of the 
broth as the lowest concentration of the drug in wells con-
taining preformed biofilm and showing no apparent growth. 
To calculate minimum biofilm eradication concentrations 
(MBECs) the biofilm in the wells were washed, resuspended 
in the same wells by adding 100 µl of sterile phosphate buff-
ered saline and the microtiter plate was shaked and then 
the sides of the wells were scraped with a pipette tip. Ten 
microliters was removed from each well, spotted onto MH 
agar plates, and incubated at 37°C. After overnight growth, 
MBECs were recorded as the lowest concentrations without 
colony growth (25).
To determine the effect of the combinations of ciprofloxacin, 
N-acetylcysteine and/or salicylate on the biofilm formation, 
50μl of the adjusted inoculum as described above was added 
to each well containing 50μl of four fold the final concentra-
tion of antimicrobial agent, NAC and salicylate, and stati-
cally incubated for 24 h to allow for biofilm formation. The 
columns 1, 11 and 12 were reserved as controls. The positive 
control was composed of 150 μl of the media and 50 μl of 
inoculum solution. The negative control was composed of 
200 μl of the same culture medium. The plates were aspi-
rated, washed and fixed as described above. To determine the 
effect of the combinations of ciprofloxacin, N-acetylcysteine 
and/or salicylate on the pre-formed biofilm, the biofilms were 
allowed to form for 24 h then the media were aspirated, 
rinsed with PBS and 50-µl of the free medium was added to 
each well containing 50μl of four fold the final concentration 
of antimicrobial agent, NAC and salicylate and incubated for 
additional 24 h. The columns 1, 11 and 12 were reserved as 
controls.
Effect of ciprofloxacin, N-acetylcysteine and 
salicylate each alone and in combination on the 
bacterial adherence to urinary catheter segments
Seven pieces of sterile silicon coated urinary catheter seg-
ments (1 cm length) were incubated in 5 ml of TSB bacte-
rial suspensions that contained 5 x 105 - 1 x 106 cfu /ml of 
bacteria to allow biofilm formation (standardized inoculum 
diluted 1:40 in TSB by adding 0.25 ml of inoculum to a 10 
ml tube of broth and 1ml of this solution added to 4 ml 
TSB to give the final volume of 5 ml). After incubation at 
37oC for 24 h, segments were removed and rinsed three 
times with phosphate buffer saline to remove non -adher-
ent bacteria (26).
To test the effect of the tested agents on the pre-formed 
biofilm, catheter segments were suspended for 24 h at 37oC 
in one of the following treatment solutions: PBS (control), 
MIC and 1/4 MIC of ciprofloxacin, salicylate (10 and 100μg/
ml), N-acetylcysteine (0.5 and 2 mg/ml), salicylate/ciprofloxa-
cin, NAC/ciprofloxacin and salicylate/NAC/ciprofloxacin. 1ml 
of each tested agent was added to the test tubes and the 
final volume was completed to 5 ml with TSB. After incuba-
tion, catheter segments were removed with sterile forceps, 
rinsed three times with PBS, vortexed in 10 ml PBS for 1 
minute and sonicated for 30 seconds to dislodge the sessile 
adherent cells. The presence of viable cells on the catheter 
segments was detected by embedding the catheter segments 
into Mueller Hinton agar plates and examining the growth 
around the segments after 48 h at 37oC.
Serial dilutions of the sonicated saline were cultured. The 
number of sessile bacteria that indicates degree of adherence 
was determined by the viable count technique (27).
To test the effect of the tested agents on the formation of 
biofilm on urinary catheters, bacterial cultures in 5 ml TSB 
were washed, diluted with fresh TSB and 1ml of this solution 
distributed into test tubes after standardizing to contain 5 x 
105 – 1 x 106 cfu/ml. Each tube contained sterile untreated 
pieces and one of the above treatment solutions were add-
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ed to each tube as described above. After 24 h incubation, 
the number of viable adherent cells were determined as de-
scribed before. Each assay was repeated at least three times.
Statistical analysis
One –Way ANOVA was employed to evaluate any significant 
difference between the values obtained without the drug 
(controls) and the values obtained in the presence of differ-
ent drug concentrations. Differences were done using SPSS, 
11 statistical software (SPSS inc., Chicago, IL). P< 0.05 was 
considered significant.
Results
MIC and MBC of planktonic isolate
The MICs and MBC of the ciprofloxacin against the tested 
strain (Ps22) were 32 and 128 µg/ml and that of salicylate 
were 500 and 1000 µg/ml while that of N-acetylcysteine 
were 8 and >8 mg/ml, respectively.
Effect of ciprofloxacin, N-acetylcysteine and 
salicylate each alone and in combination on the 
bacterial adherence to microtiter plates
Regarding the effect of ciprofloxacin on the biofilm forma-
tion, the obtained results revealed that in concentrations 
above 2MIC no detectable biofilm formed and in presence 
of 2MIC little detectable biofilm formation up to 13.9% was 
observed. In presence of MICs, the percent of reduction in 
biofilm formation was 74.36% compared to the controls. 
Sub-MICs, significantly inhibited the adherence in a dose 
dependent manner. The percent of reduction in biofilm for-
mation was 69.55% in presence of 1/2 MIC and 42.37% in 
presence of 1/8 MIC. Concerning the growth of bacteria in 
biofilm, no inhibitory effect on the growth at 1/4MIC and 
1/8 MIC and the reduction in the above concentrations were 
compensated by the slime index values which were consistent 
and correlated with the reduction of biofilm produced by 
ciprofloxacin. (Figure 1 [a]).
Concerning the eradication of the preformed biofilm from 
plastic surfaces, treatment with concentrations above MIC of 
ciprofloxacin significantly disrupted the biofilms completely in 
Figure (1):  Effect of different MIC concentrations of ciprofloxacin on biofilm formation or pre-formed biofilms of P. aeruginosa isolate 
Ps22 (a) Biofilm formation, growth and slime index. (b) Remained pre-formed biofilm, growth and slime index. Results are 
expressed as mean percentage of growth formed or remained which calculated as (100 x OD490 treated/ OD490 positive 
control) before aspiration of the broth from microtiter plates. Mean percentage of biofilm formed or remained calculated 
as (100 x OD490 treated/ OD490 positive control). SI calculated as 100 x (mean density of biofilm with ciprofloxacin/ mean 
growth with ciprofloxacin) / (mean density of biofilm without ciprofloxacin/ mean growth without ciprofloxacin). 
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Figure (2):  Effect of different salicylate concentrations on biofilm formation or pre-formed biofilms of P. aeruginosa isolate Ps22 (a) 
Biofilm formation, growth and slime index. (b) Remained pre-formed biofilm, growth and slime index. Results are expressed 
as mean percentage of growth formed or remained which calculated as (100 x OD490 treated/ OD490 positive control) 
before aspiration of the broth from microtiter plates. Mean percentage of biofilm formed or remained calculated as (100 x 
OD490 treated/ OD490 positive control). Mean percentage of SI calculated as 100 x (mean density of biofilm with salicylate/ 
mean growth with salicylate) / (mean density of biofilm without salicylate/ mean growth without salicylate). 
Figure (3):  Effect of different N-acetylcysteine concentrations on biofilm formation or pre-formed biofilms of P. aeruginosa isolate 
Ps22 (a) Biofilm formation, growth and slime index. (b) Remained pre-formed biofilm, growth and slime index. Results are 
expressed as mean percentage of growth formed or remained which calculated as (100 x OD490 treated/ OD490 positive 
control) before aspiration of the broth from microtiter plates. Mean percentage of biofilm formed or remained calculated 
as (100 x OD490 treated/ OD490 positive control). Mean percentage of SI calculated as 100 x (mean density of biofilm with 
NAC/ mean growth with NAC) / (mean density of biofilm without NAC/ mean growth without NAC). 
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Figure (4):  Effect of MIC and sub-MIC concentrations of ciprofloxacin, N-acetylcysteine and salicylate alone and in combinations on 
biofilm or pre-formed biofilm of P. aeruginosa isolate Ps22 (a) Biofilm formation (b) Biofilm eradication. Results are ex-
pressed as mean percentage of reduction in biofilm formation on treated wells compared with that on untreated wells as 
follows: 100 - ( ODtreated well/ODuntreated well x 100). 
Figure (5):  Effect of adding salicylate to ciprofloxacin / N-acetylcysteine combination on biofilm or pre-formed biofilm of P. aeruginosa 
isolate Ps22 (a) Biofilm formation (b) Biofilm eradication. Results are expressed as mean percentage of reduction in biofilm 
formation on treated wells compared with that on untreated wells as follows: 100 - ( ODtreated well/ODuntreated well x 100). 
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presence of 16MIC and 8MIC, 77.69% in presence of 4MIC 
and 60.22% in presence of 2MIC. In presence of MICs the 
percents of biofilm eradication were about 53.77%. In pres-
ence of sub-MICs, 1/2MIC and 1/4MIC of the tested antimi-
crobial agents the percents of biofilm eradication were 47.72 
and 42.13%, respectively. Regarding the growth of the tested 
isolate, in presence of 1/2MIC and 1/4MIC of ciprofloxacin, 
no inhibitory effect on the growth compared to the positive 
control was observed. In general in presence of all supra-
MICs, MICs and sub-MICs of the tested antimicrobial agents, 
the reduction in the growth was correlated with the reduc-
tion in pre-formed biofilms as indicated by the slime index 
percentage (Figures 1 [b]). 
The MBIC (256 µg/ml) of ciprofloxacin against the biofilm 
of the tested isolate Ps22 was 8 fold higher than the plank-
tonic MIC. The MBEC was the same than the MBIC so no 
tolerance to these antimicrobials from the biofilm as in the 
planktonic case.
Salicylate inhibited the biofilm production and disrupted the 
pre-formed biofilm of Ps22 on a dose dependent manner 
with no or little effect on the viability of the bacteria during 
biofilm formation at the range of concentrations 50-150 µg/
ml and in the pre-formed biofilms in concentration below 
100 µg/ml. Salicylate inhibited biofilm formation by 33.92 at 
concentration (10 µg/ml) and 68% at concentration (100 µg/
ml). The reduction of biofilm formation was significant at the 
range of concentrations 10 - 100 µg/ml (P < 0.01). Salicylate 
disrupted the pre-formed biofilm by 19.76% at concentration 
(10 µg/ml) and 64% at concentration (100 µg/ml) (Figure 2 
[a & b]). 
NAC did not exhibit significant changes in the bacterial growth 
during biofilm formation or in the pre-formed biofilms except 
at the highest concentration tested (8 mg/ml). It inhibited the 
biofilm production and eradicated the pre-formed biofilms in 
a dose dependent manner till the concentration (2 mg/ml). 
Above this concentration, slight or no further increase in the 
biofilm inhibition or eradication was observed. Concerning 
the capacity to produce biofilms and persistence of the pre-
formed biofilms, at concentrations 0.5 mg/ml and 2 mg/ml 
the percent of reduction in biofilm formation was 48.62% 
and 71.43, respectively while the percent of eradication of 
pre-biofilm was 43.55% and 67.12, respectively (Figures 3 
[a & b]). 
The effect of the combination of ciprofloxacin at MIC, 1/2MIC, 
1/4MIC, 1/8MIC with NAC and/or salicylate on adhesion to 
plastic microtiter plates were studied and the results indicated 
that combinations of NAC in both concentration, 0.5 (mg/ml) 
and 2 (mg/ml) showed synergism with ciprofloxacin and the 
percent of reduction in biofilm formation or the percent of 
eradication of pre-formed biofilms was increased by increas-
ing both the concentration of NAC and ciprofloxacin. When 
ciprofloxacin combined with NAC (0.5 mg/ml) the percent 
of reduction in biofilm formation was (83.71 %) with MIC, 
(80.93 %) with 1/2MIC, (70 %) with 1/4MIC and (60.83 %) 
with 1/8MIC and when ciprofloxacin combined with NAC 
(2 mg/ml) the percent of reduction in biofilm formation was 
(91.23 %) with MIC, (90.84 %) with 1/2MIC, (83.24 %) 
with 1/4MIC and (77.23 %) with 1/8MIC (Figures 4 [a]) The 
percent of biofilm eradication when ciprofloxacin combined 
with NAC (0.5 mg/ml) was (77 %) with MIC, (72.81 %) with 
1/2MIC, (68.5 %) with 1/4MIC and (64 %) with 1/8MIC and 
when combined with NAC (2 mg/ml) was (84.58 %) with 
MIC, (82.07 %) with 1/2MIC, (81.91 %) with 1/4MIC and 
(74.21 %) with 1/8MIC (Figure 4[b]). 
There was either no or slight increase in the ciprofloxacin anti-
biofilm effect was observed when combined with salicylate 
in either concentration, 10 (µg/ml) or 100 (µg/ml). Of all the 
above combinations, high percent of reduction in the forma-
tion of biofilms or eradication of pre-formed biofilms was 
observed when ciprofloxacin combined with NAC (2 mg/ml) 
(Figures 4 [a & b]. 
By adding salicylate to the combination of ciprofloxacin with 
NAC it was found that the percent of reduction in biofilm 
formation or eradication was significantly increased with all 
combinations. The increase in the percent of biofilm reduc-
tion or eradication was dose dependent. The best combina-
tion was ciprofloxacin/ NAC (2mg/ml)/ salicylate (100 µg/ml) 
with a percent of reduction in biofilm formation 98.56% 
and a percent of eradication of pre-formed biofilms 96.81% 
followed by the combination ciprofloxacin/ NAC (2mg/ml)/ 
salicylate (10 µg/ml) with a percent of reduction in biofilm for-
mation 95.44% and a percent of eradication of pre-formed 
biofilms 93.25% (Figures 5 [a & b]. 
Effect of ciprofloxacin, N-acetylcysteine and 
salicylate each alone and in combination on the 
bacterial adherence to urinary catheter segments
The tested isolate adhered well to the catheter segments. 
The inhibitory effect of ciprofloxacin, NAC and salicylate were 
found to be concentration dependent. Ciprofloxacin used at 
MIC inhibited biofilm synthesis by 67.35% and eradicated 
the biofilms pre-adhered to the catheter by 65.83% in all the 
tested strains. At 1/4 MIC, reduction of biofilm synthesis was 
55.22% and disruption of pre-adhered biofilms was 51.55%. 
NAC and salicylate showed a significant inhibitory effect on 
biofilm production and eradication. At a concentration of 0.5 
mg/ml of NAC, reduction of biofilm synthesis was 49.25% 
and eradication of pre-formed biofilms was up to 40.37% 
while at 2 mg/ml biofilm synthesis was reduced by 62% 
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and pre-adhered biofilm was disrupted by up to 61.49%. 
Salicylate At a concentration of 10 µg/ml, reduced biofilm 
synthesis by 57.01% and eradicated pre-adhered biofilms by 
29.19% while at 100 µg/ml biofilm synthesis was reduced 
by 68.35% and pre-formed biofilms was disrupted by up to 
62.73% (Tables 1).
Concerning the combinations of ciprofloxacin with NAC, the 
results of all the combinations confirmed the results obtained 
by spectrophotometric assay in which, a concentration de-
pendent increase in the reduction of biofilm synthesis and 
eradication of pre-adhered biofilms was shown. Combina-
tions of ciprofloxacin with salicylate also confirmed the results 
obtained by spectrophotometric assay in which, no or slight 
increase in the anti-biofilm effect was observed by these 
combinations in either concentration, 10 (µg/ml) or 100 (µg/
ml). High percent of reduction in biofilm formation or pre-
adhered biofilm eradication was observed when ciprofloxacin 
combined with NAC (2 mg/ml) (Table 1). A synergistic effect 
was observed when adding salicylate to the combinations of 
Table 1.  Effect of combinations of ciprofloxacin, N-acetylcysteine and salicylate together on biofilm formation and pre-formed 
biofilm on urinary catheter.
Pre-formed biofilm Biofilm formation
Reagent
 eradication%
Viable cell counts 
Mean cfu x 104 
± SD
% reduction
Viable cell counts
Mean cfu x 104 
± SD
- 161 ± 2.51 - 67 ± 1.5 Control
40.37 96 ± 5.77* 49.25 34 ± 2.3* NAC (0.5mg/ml)
61.49 62 ± 4.61* 62.08 25.4 ± 4.1* NAC (2mg/ml)
29.19 114 ± 1.73* 57.01 28.8 ± 6.3* Sal (10µg/ml)
62.73 60 ± 3.46* 68.35 21.2 ± 4.6* Sal (100µg/ml)
65.83 55.6 ± 2.25* 67.35 21.8 ± 2.8* Cipro MIC a
77.01 37 ± 1.73** 83.71 10.9 ± 1.3** Cipro+NAC (0.5)
85.45 23.4 ± 4.35** 89.14 7.2 ± 1.1** Cipro+NAC (2)
69.56 49 ± 4.61** 69.10 20.7 ± 5.1** Cipro+Sal (10) 
73.04 43 ± 3.46** 73.73 17.6 ± 2.7** Cipro+Sal (100)
90.8 14.8 ± 0.63** 90.89 6.1 ± 0.46** Cip/NAC 0.5/ Sal10
96.02 6.4 ± 0.28** 98.53 1.4 ± 0.23** Cip/NAC 0.5/Sal100
93.22 10.9 ± 0.46** 95.84 2.7 ± 0.57** Cip /NAC 2 / Sal10
98.44 2.5 ± 0.35** 99.56 0.29 ± 0.04** Cip /NAC 2/ Sal100
51.55 78 ± 1.15* 55.22 30 ± 2.3* Cipro 1/4MIC 
68.94 50 ± 2.88** 70.14 20 ± 4.0** Cipro+NAC (0.5)
79.50 33 ± 2.3** 82.53 11.7 ± 2.5** Cipro+NAC (2)
56.52 70 ± 5.19** 60.89 26.2 ± 3.5** Cipro+Sal (10)
65.83 55 ± 4.0** 71.79 18.9 ± 5.7** Cipro+Sal (100)
81.36 30 ± 4.61** 81.64 12.3 ± 0.57** Cip/NAC 0.5/ Sal10
89.93 16.2 ± 0.28** 93.58 4.3 ± 0.34** Cip/NAC 0.5/Sal100
89.87 16.3 ± 0.57** 92.98 4.7 ± 0.28** Cip /NAC 2 / Sal10
92.11 12.7 ± 0.46 93.28 4.5 ± 0.2** Cip /NAC 2/ Sal100
a: MIC for Ps22= 32 µg/ml.
* P<0.05: Significant value, compared to controls. ** P<0.01: Significant value, compared to controls, ciprofloxacin group, salicylate group and NAC group.
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ciprofloxacin with NAC and the best combination was cip-
rofloxacin/ NAC (2mg/ml)/ salicylate (100 µg/ml) followed by 
the combination ciprofloxacin/ NAC (2mg/ml)/ salicylate (10 
µg/ml) (Table 1).
Discussion 
The presence of a biotic material stimulates biofilm produc-
tion by some micro-organisms, rendering device associated 
infections more difficult to treat (5). Urinary catheters used in 
clinical settings could be favorable to encrustation and biofilm 
formation (2). Currently used approaches for the treatment 
of catheter related infection include systemic antibiotics with 
or without antimicrobial solution, which may not completely 
eradicate catheter associated infections, even at high concen-
trations, since the biofilm matrix that nests the pathogens on 
the surface of the indwelling catheter may remain partially 
or entirely undisrupted (28). It has been estimated that bac-
teria that are embedded in biofilms are 1000 times more 
resistant to many antibiotics than when they are in a free 
floating planktonic form (25). The antimicrobial activity can 
be enhanced by combining antibiotics with other compounds 
such as salicylate or NAC (8, 29, 30). The ciprofloxacin antimi-
crobial is non-toxic, orally administered, has long lasting bac-
tericidal activity and is frequently used in urological patients 
for the treatment of urinary tract infection (31).
In the present study trials were carried out to comparatively 
evaluate the ability of salicylate and or NAC to enhance the 
effect of ciprofloxacin against the biofilm formation and the 
preformed biofilm of P. aeruginosa isolate Ps22 on urinary 
catheters. Two methods were used, the spectrophotometric 
method using microtiter plates and the viable count method 
using urinary catheter segments.
The microtiter plate method revealed that high concentration 
(4MIC) of ciprofloxacin needed to achieve 100% inhibition of 
biofilm formation. On the other hand MIC and sub-MIC levels 
used achieve 74.36% and not less than 40% inhibition of 
biofilm formation, respectively. The well established biofilms 
on microtiter plates revealed more resistance to ciprofloxacin 
and 8MIC of this antimicrobial (256 µg/ml) was needed to 
achieve 100% removal of the biofilms. No visible growth was 
observed in the wells at this concentration so it is considered 
as MBIC which was 8 fold higher than planktonic MIC. The 
MBEC was found to be the same as MBIC and two fold 
higher than the planktonic MBC. At MIC and sub-MIC levels 
the percent of eradication of pre-formed biofilms was 53.7% 
and not less than 40%, respectively.
The efficiency of ciprofloxacin in preventing the bacterial ad-
herence to the surface of indwelling devices and eradicating 
the pre-attached cells was reported previously. Pretreatment 
of urinary tract silicone latex catheters in-vitro with sub-in-
hibitory concentration (0.1µg/ml) of ciprofloxacin for 1, 24 
and 48h significantly reduced the adherence of P. aeruginosa 
AK1. In addition, the adherent biofilms of P. aeruginosa were 
eradicated by 24 h of interaction with 50 and 100 µg/ml of 
ciprofloxacin (27). 
The effect of sub-inhibitory concentrations of ciprofloxacin 
on glycocalyx formation and adherence of different types of 
bacteria has been studied by various investigators. The ef-
ficiency of the sub-inhibitory concentrations of ciprofloxacin 
on the biofilm formation and adherence of enterobacterial 
clinical isolates (32), P. fluorescens (33), has been reported.
 Higher concentrations of fluoroquinolones needed to eradi-
cate the preformed biofilms and this was also reported 
by Yassien &  Khardori (34), while 16 MIC of ciprofloxacin 
showed completely eradication of biofilms of P. aeruginosa 
on Teflon sheets and on catheters (35). The activity of fluo-
roquinolones in eradicating the preformed biofilms was also 
observed during studying their effect on the adherence of 
Stenotrophomonas maltophilia (36). 
MBIC values higher than MIC were also noticed by other in-
vestigators who found that for P. aeruginosa collection of 20 
strains 4-fold to 512-fold higher MBIC values than MIC were 
obtained for all tested antibiotics including ciprofloxacin and 
amikacin (37). Some authors observed that P. aeruginosa in 
biofilm showed a 4-fold greater resistance against ciprofloxa-
cin and gentamycin compared with free-living forms (28). 
Goto et al. (1999) observed that both ciprofloxacin and levo-
floxacin eradicated biofilm bacteria completely from Teflon 
catheter in artificial urine by 24 hours at a concentration 32 
times the MBC (38).
In the present work, salicylate and NAC inhibited the bio-
film production and disrupted the pre-formed biofilm from 
microtiter plates in a dose dependent manner with no or 
little effect on the viability of these bacteria during biofilm 
formation. These results matched the previous studies on the 
effect of salicylate on bacterial biofilms. Farber & Wolff (1992) 
reported that SA inhibited adherence (55%), growth, and bio-
film production of Staphylococcus epidermidis (15). A second 
study by Farber et al. (1995) further illustrated that NSAIDs, 
including sodium salicylate, inhibit S. epidermidis and P. aeru-
ginosa biofilms production on contact lenses, lens cases, and 
commonly used medical polymers in a dose-related manner 
(39) and this manner also observed by other authors (17, 18). 
NAC decreases biofilm formation by a variety of bacteria and 
eradicating the pre-attached cells (8, 9, 24, 40) and reduces 
the production of an extracellular polysaccharide matrix, 
while promoting the disruption of mature biofilms (8, 10). 
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This study showed that all combinations of ciprofloxacin with 
NAC in both concentration, 0.5 (mg/ml) and 2 (mg/ml) have 
synergism while no or slight increase in the anti-biofilm effect 
was observed when ciprofloxacin was combined with salicy-
late in either concentration, 10 (µg/ml) or 100 (µg/ml). High 
percent of reduction in the biofilm formation and high per-
cent of eradication of pre-formed biofilm was observed when 
ciprofloxacin combined with NAC (2 mg/ml). The addition of 
salicylate to the ciprofloxacin/ NAC combinations achieved 
percent of inhibition of biofilm formation up to 98.56% and 
percent of eradication of pre-formed biofilms up to 96.81%. 
These results were confirmed by the viable count method 
using urinary catheter segments.
The use of salicylate and NAC in combination with other an-
timicrobials to reduce the biofilm formation or eradicate the 
pre-formed biofilms was investigated in some studies. The 
combination of salicylate with vancomycin inhibited biofilm 
formation and eradicated pre-formed biofilm of S. epidermid-
is (RP62A) (29). The combination of NAC with fosfomycin was 
reported by Marchese et al. (2003) to produce a synergistic 
effect influencing both the formation of biofilms and sessile 
cell viability (8). The combination of NAC with tigecycline was 
found to have synergistic effect against methicillin-resistant 
S. aureus and S. epidermidis (30). The combination of NAC 
with ciprofloxacin was reported to inhibit biofilm production 
and to disrupt pre-formed biofilms from urethral stents. They 
proved that NAC enhancing the therapeutic effect of cipro-
floxacin by degrading the Extracellular polysaccharides matrix 
of biofilm. To the best of our knowledge, the use of the 
combination of the two drugs, salicylate and NAC together 
with any antimicrobial to treat or eradicate bacterial biofilms 
have not been previously reported (26). 
NAC is a well established antioxidant agent (7) that disrupts 
disulphide bonds in mucus and reduces the viscosity of secre-
tions. NAC reaches appreciable concentrations in the bladder, 
promoting the dissolution of urinary mucus, a positive effect 
especially relevant for those patients that require intermittent 
catheterization (41). NAC used in this study at concentra-
tions easily achievable in urine. The concentration of salicylate 
(100µg/ml) used in this study within the therapeutic level 
of aspirin. 300-mg aspirin tablet taken orally yields a whole 
blood concentration of 75 µg/ml, or 225 µg/ml for a maxi-
mum recommended therapeutic dose of three tablets. The 
blood level of 2mM for salicylate and acetylsalicylate is rec-
ommended for the treatment of rheumatic fever (42).
In conclusion, our results revealed the great effect of the 
tested combinations on inhibition of bacterial adherence and 
in removal of pre-formed biofilms. Salicylate and N-acetylcys-
teine increase the therapeutic efficacy of ciprofloxacin when 
both used in combination. The proved effect of this combina-
tion in preventing biofilm formation can be used as coating 
for the urinary catheter surface. In addition, its disruptive ef-
fect on the formed biofilms can be utilized as a catheter lock 
solution for biofilm treatment and removal. These drugs may 
form a new strategy for the treatment the serious problem 
of biofilm formation after conducting in vivo animal models 
and clinical trials to demonstrate the efficacy and safety of 
these combinations in patients. 
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
© Under License of Creative Commons Attribution 3.0 License
2012
Vol. 2 No. 1:4
doi: 10.3823/708
11
iMedPub Journals
Our Site: http://www.imedpub.com/
References
 1. Saint, S, Veenstra, DL, Sullivan, SD, Chenoweth, C and Fendrick, AM. 
The potential clinical and economic benefits of silver alloy urinary 
catheters in preventing urinary tract infection. Arch. Intern. Med. 
2000; 160(17): 2670-2675.
 2. Sofer, M and Denstedt, JD. Encrustation of biomaterials in the urinary 
tract. Curr. Opin. Urol. 2000; 10(6):563-569.
 3. Shaw, KJ, Rather, PN, Hare, RS and Miller, GH. Molecular genetics 
of aminoglycoside resistance genes and familial relationships of the 
aminoglycoside-modifying enzymes. Microbiol. Rev. 1993; 57(1):138-
163.
 4. Dworniczek, E, Kuzko, K, Mróz, E, Wojciech, Ł, Adamski, R, 
Sobieszczaska, B and Seniuk, A. Virulence factors and in vitro 
adherence of Enterococcus strains to urinary catheters. Folia Microbiol. 
(Praha). 2003; 48(5):671-678.
 5. Filloux, A and Vallet, I. Biofilm: set-up and organization of a bacterial 
community. Med. Sci.(Paris). 2003; 19(1):77-83.
 6. Wagenlehner, FM and Naber, KG. Emergence of antibiotic resistance 
and prudent use of antibiotic therapy in nosocomially acquired urinary 
tract infections. Int. J. Antimicrob. Agents. 2004; 23 (Suppl 1):S24- 
S29.
 7. Fink, MP. Role of reactive oxygen and nitrogen species in acute 
respiratory distress syndrome. Curr. Opin. Crit. Care. 2002; 8: 6-11.
 8. Marchese, A, Bozzolasco, M, Gualco, L, Debbia, EA, Schito, GC and 
Schito, AM. Effect of fosfomycin alone and in combination with 
N-acetylcysteine on E. coli biofilms. Intern. J. Antimicrob. Agent. 2003; 
22:S95-S100.
 9. Schwandt, LQ, Van Weissenbruch, R, Stokroos, I, Van der Mei, HC, 
Busscher, HJ and Albers, FW. Prevention of biofilm formation by dairy 
products and N-acetylcysteine on voice prostheses in an artificial 
throat. Acta Otolaryngol. 2004; 124(6):726-731.
 10. Olofsson, AC, Hermansson, M and Elwing, H. N-acetyl-L-cysteine 
affects growth, extracellular polysaccharide production, and bacterial 
biofilm formation on solid surfaces. Appl. Environ. Microbiol. 2003; 
69: 4814-4822.
 11. Oldemeyer, JB, Biddle, WP, Wurdeman, RL, Mooss, AN, Cichowski, E, 
and Hilleman, DE. Acetylcysteine in the prevention of contrast induced 
nephropathy after coronary angiography. Am. Heart J. 2003; 146: 
E23.
 12. Marzullo, L. An update of N-acetylcysteine treatment for acute 
acetaminophen toxicity in children. Curr. Opin. Pediatr. 2005; 17: 
239–245.
 13. Kao, LW, Kirk, MA, Furbee, RB, Mehta, NH, Skinner, JR and 
Brizendine, EJ. What is the rate of adverse events after oral 
N-acetylcysteine administered by the intravenous route to patients 
with suspected acetaminophen poisoning? Ann. Emerg. Med. 2003; 
42: 741–750.
 14. Paterson, JR, Srivastava, R, Baxter, GJ, Graham, AB and Lawrence, JR. 
Salicylic acid content of spices and its implications. J. Agricult. Food 
Chem. 2006; 54: 2891–2896.
 15. Farber, B and Wolff, A. The use of nonsteroidal anti-inflammatory 
drugs to prevent adherence of Staphylococcus epidermidis to medical 
polymers. J. Infect. Dis. 1992; 166: 861–865.
 16. Muller, E, Al-Attar, J, Wolff, AG and Farber, BF. Mechanism of 
salicylate-mediated inhibition of biofilm in Staphylococcus epidermidis. 
J. Infect. Dis. 1998; 177(2): 501-503.
 17. Tomlinson, A, Simmons, P, Seal, D, McFadyen, A. Salicylate inhibition 
of Acanthamoeba attachment to contact lenses. Opthalmology. 2000; 
107:112–117.
 18. Bandara, BM,  Sankaridurg, PR and  Willcox, MD. Non-steroidal anti 
inflammatory agents decrease bacterial colonisation of contact lenses 
and prevent adhesion to human corneal epithelial cells. Curr. Eye Res. 
2004; 29(4-5): 245-251.
 19. El-Azizi, M, Rao, S, Kanchanapoom, T and Khardori, N. In vitro 
activity of vancomycin, quinupristin/dalfopristin, and linezolid against 
intact and disrupted biofilms of staphylococci. Ann. Clin. Microbiol. 
Antimicrob. 2005; 4:2.
 20. Koneman, EW, Allen, SD, Janda, WM, Schreckenberger, PC and Winn, 
WC. 1992; Color Atlas and Textbook of Diagnostic Microbiology. J.B. 
Lippincott Company, Philadelphia, PA.
 21. Christensen, GD, Simpson, WA, Younger, JJ, Baddour, LM, Barrett, 
FF, Melton, DM and Beachey, EH. Adherence of coagulase-negative 
staphylococci to plastic tissue culture plates: a quantitative model for 
the adherence of staphylococci to medical devices. J. Clin. Microbiol. 
1985; 22: 996-1006.
 22. Clinical and Laboratory Standards Institute 2006. Approved standard: 
M7 – A7. Methods for dilution antimicrobial susceptibility tests 
for bacteria that grow aerobically, 7th ed. Clinical and Laboratory 
Standards Institute. Wayne, PA.
 23. Harrison, JJ, Turner, RJ and Ceri, H. High-throughput metal 
susceptibility testing of microbial biofilms. BMC Microbiol. 2005; 5: 53.
 24. Perez-Giraldo, C, Rodriguez-Benito, A, Moran, FJ, Hurtado, C, Blanco, 
MT and Gomez-Garcia, AC. Influence of N acetylcysteine on the 
formation of biofilm by Staphylococcus epidermidis. J. Antimicrob. 
Chemother. 1997; 39: 643–646.
 25. Ceri, H, Olson, M, Morck, D, Storey, D, Read, R, Buret, A and Olson, B. 
The MBEC assay system: multiple equivalent biofilms for antibiotic and 
biocide susceptibility testing. Methods Enzymol. 2001; 337: 377-385.
 26. El-Feky, MA, El-Rehewy, MS, Hassan, MA, Abolella, HA, Abd El-Baky, 
RM and Gad, GF. Effect of ciprofloxacin and N-acetylcysteine on 
bacterial adherence and biofilm formation on ureteral stent surfaces. 
Pol. J. Microbiol. 2009; 58(3): 261-267.
 27. Reid, G, Sharma, S, Advikolanu, K, Tieszer, C, Martin, RA and Bruce, 
AW. Effects of ciprofloxacin, norfloxacin, and ofloxacin on In Vitro 
adhesion and survival of Pseudomonas aeruginosa AK1 on urinary 
catheters. Antimicrob. Agents Chemother. 1994; 38: 1490–1495.
 28. Agarwal, G, Kapil, A, Kabra, SK, Das, BK and Dwivedi, SN. In 
vitro efficacy of ciprofloxacin and gentamicin against a biofilm of 
Pseudomonas aeruginosa and its free-living forms. Natl. Med. J. India. 
2005; 18(4): 184-186.
 29. Polonio, RE, Mermel, LA, Paquette, GE and Sperry, JF. Eradication of 
biofilm-forming Staphylococcus epidermidis (RP62A) by a combination 
of sodium salicylate and vancomycin. Antimicrob. Agents Chemother. 
2001; 45(11): 3262-3266.
 30. Aslam, S, Trautner, BW, Ramanathan, V and Darouiche, R O. 
Combination of tigecycline and N-acetylcysteine reduces biofilm-
embedded bacteria on vascular catheters. Antimicrob. Agents 
Chemother. 2007; 21(4):1556–1558.
 31. Oliphant, CM. Quinolones: a comprehensive review. Am. Fam. 
Physician. 2002; 65: 455–464.
 32. Bret, L and Di Martino, P. Effect of ceftazidime, amikacin and 
ciprofloxacin on biofilm formation by some enterobacterial clinical 
isolates. Chemother. 2004; 50(5): 255-259. 
 33. Dynes, JJ, Lawrence, JR, Korber, DR, Swerhone, GD, Leppard, GG 
and Hitchcock, AP. Morphological and biochemical changes in 
Pseudomonas fluorescens biofilms induced by sub-inhibitory exposure 
to antimicrobial agents. Can. J. Microbiol. 2009; 55(2):163-178.
 34. Yassien M and Khardori, N. Interaction between biofilms formed by 
Staphylococcus epidermidis and quinolones. Diagn. Microbiol. Infect. 
Disease. 2001; 40(3):79-89.
 35. Abdi-Alia, A, Mohammadi-Mehrb, M and Agha Alaei, Y. Bactericidal 
activity of various antibiotics against biofilm-producing Pseudomonas 
aeruginosa. Int. J. Antimicrob. Agents. 2006; 27 (3): 196 - 200.
 36. Di Bonaventura, G, Spedicato, I, D’Antonio, D, Robuffo, I and 
Piccolomini, R. Biofilm formation by Stenotrophomonas maltophilia: 
modulation by quinolones, trimethoprim-sulfamethoxazole, and 
ceftazidime. Antimicrob. Agents Chemother. 2004; 48(1):151-160.
iMedPub Journals
Our Site: http://www.imedpub.com/
12 © Under License of Creative Commons Attribution 3.0 License
2012
Vol. 2 No. 1:4
doi: 10.3823/708
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
 37. Cernohorská, L and Votava, M. Antibiotic synergy against biofilm-
forming Pseudomonas aeruginosa. Folia. Microbiol. (Praha). 2008; 
53(1):57-60.
 38. Goto, T, Nakame, Y, Nishida, M and Ohi, Y. In vitro bactericidal 
activities of beta-lactamases, amikacin, and fluoroquinolones against 
Pseudomonas aeruginosa biofilm in artificial urine. Urol. 1999; 53(5): 
1058-1062.
 39. Farber, B, Hsieh, H, Donnenfeld, E, Perry, H, Epstein, A and Wolff, 
A. A novel antibiofilm technology for contact lens solutions. 
Ophthalmology 1995; 102: 831–837.
 40. Mansouri, MD and Darouiche RO. In vitro antimicrobial activity of 
N-acetylcysteine against bacteria colonising central venous catheters. 
Int. J. Antimicrob. Agents 2007; 29(4): 471–483.
 41. Gillon, G and Mundy, AR. The dissolution of urinary mucus after 
cystoplasty. Br. J. Urol. 1989; 63: 372- 374.
 42. Axon, JMC and Huskisson, EC. 1992. Use of aspirin in inflammatory 
diseases. In Aspirin and Other Salicylate, (Vane, J.R. and Botting, R.M., 
Eds), pp.295 – 320. Chapman& Hall, London.
✓ The Journal is an open access peer-reviewed journal that publishes 
scienti	c papers about all aspects of antimicrobials. The journal will 
publish original research articles, reviews, brief reports and case reports 
dealing with basic and clinical antibacterial agents, antiviral, antiproto-
zoals, antituberculuous, antifungal and antihelminthes agents.
✓ All manuscripts must be prepared in English, and are subject to a 
rigorous and fair peer-review process. Accepted papers will immediately 
appear online.
✓ The journal aims to advance the knowledge, attitude and the research 
of chemotherapy in the Arabic world in cooperation with international, 
national scienti	c and public societies as well as research centers with 
similar aims and objectives. 
Submit your manuscript here:
http://www.iajaa.org
Publish with iMedPub
http://www.imedpub.com
At Medicalia.org
Doctors exchange clinical experiences, review 
their cases and share clinical knowledge. You 
can also access lots of medical publications for 
free. Join Now! http://medicalia.ning.com/
Follow us:
